首页> 美国卫生研究院文献>Springer Open Choice >Non-invasive bladder volume measurement for the prevention of postoperative urinary retention: validation of two ultrasound devices in a clinical setting
【2h】

Non-invasive bladder volume measurement for the prevention of postoperative urinary retention: validation of two ultrasound devices in a clinical setting

机译:预防术后尿volume留的无创膀胱容积测量:在临床环境中验证两个超声设备

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Ultrasound scanning of bladder volume is used for prevention of postoperative urinary retention (POUR). Accurate assessment of bladder volume is needed to allow clinical decision-making regarding the need for postoperative catheterization. Two commonly used ultrasound devices, the BladderScan® BVI 9400 and the newly released Prime® (Verathon Medical®, Bothell, WA, USA), with or without the ‘pre-scan’ option, have not been validated in clinical practice. The aim of this study was to assess the performance of these devices in daily clinical practice. Between June and September 2016 a prospective observational study was conducted in 318 surgical patients (18 years or older) who needed a urinary catheter perioperatively for clinical reasons. For acceptable performance, we required that the volume as estimated by the BladderScan® differs by no more than 5% from the actual urine volume after catheterization. The Schuirmann’s two one-sided test was performed to assess equivalence between the BladderScan® estimate and catheterization. The BVI 9400® overestimated the actual bladder volume by + 17.5% (95% CI + 8.8 to + 26.3%). The Prime® without pre-scan underestimated by − 4.1% (95% CI − 8.8 to + 0.5%) and the Prime® with pre-scan underestimated by − 6.3% (95% CI − 11.6 to − 1.1%). This study shows that while both ultrasound devices were able to approximate current bladder volume, both BVI 9400® and Prime®—with and without pre-scan—were not able to measure the actual bladder volume within our predefined limit of ± 5%. Using the pre-scan feature of the Prime® did not further improve accuracy.
机译:膀胱容积的超声扫描可用于预防术后尿retention留(POUR)。需要对膀胱容量进行准确评估,以做出有关术后置管需要的临床决策。 BladderScan®BVI 9400和新发布的Prime®(VerathonMedical®,美国华盛顿州博塞尔)两种带有或不带有“预扫描”选项的常用超声设备尚未在临床实践中得到验证。这项研究的目的是评估这些设备在日常临床实践中的性能。在2016年6月至2016年9月之间,对318名因临床原因需要围手术期导尿管的外科手术患者(18岁或18岁以上)进行了一项前瞻性观察研究。为了获得可接受的性能,我们要求BladderScan®估算的体积与导尿后的实际尿体积相差不超过5%。进行了Schuirmann的两项单侧测试,以评估BladderScan®评估与导管插入术之间的等效性。 BVI9400®高估了膀胱实际体积+ 17.5%(95%CI +8.8到26.3%)。不带预扫描的Prime®低估了-4.1%(95%CI-8.8至+ 0.5%),带预扫描的Prime®低估了-6.3%(95%CI-11.6至-1.1%)。这项研究表明,尽管两个超声设备都能够近似当前膀胱体积,但BVI9400®和Prime®(带有和不带有预扫描)都无法在我们的±5%的预定范围内测量实际膀胱体积。使用Prime®的预扫描功能无法进一步提高准确性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号